Cyclosporine is associated with endothelial dysfunction but not with platelet activation in renal transplantation

Netherlands Journal of Medicine

Volumn 59, Issue 1, 2001, Pages 6-15

  Schrama, Yvonne C ^a   Van Dam, Thea ^a   Fijnheer, Rob ^a   Hené, Ronald J ^a   De Groot, Philip ^a   Rabelink, Ton J ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN A; MARKER; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PADGEM PROTEIN; PREDNISONE; VON WILLEBRAND FACTOR;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; DRUG WITHDRAWAL; ENDOTHELIUM LESION; FEMALE; FLOW CYTOMETRY; HIGH RISK PATIENT; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; RECIPIENT; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE MEMBRANE; THROMBOTIC THROMBOCYTOPENIC PURPURA;

ADULT; AGED; ANALYSIS OF VARIANCE; BIOLOGICAL MARKERS; CYCLOSPORINE; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PLATELET ACTIVATION; PROSPECTIVE STUDIES; SELECTINS; STATISTICS, NONPARAMETRIC; VON WILLEBRAND FACTOR;

EID: 0034960980     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0300-2977(01)00127-9     Document Type: Article

References (41)

1. A randomized clinical trial of cyclosporine in cadaveric renal transplantation. Analysis at three years. The Canadian Multicentre Transplant Study Group
2. The factor V Leiden (R5060) mutation and risk of thrombosis in renal transplant recipients
3. Vascular damage and factor VIII-related antigen in the rheumatic disease
4. Factor VIII-related antigen in the assessment of vasculitis
5. The origin of P-selectin as a circulating plasma protein
6. Progressive vascular damage in hypertension is associated with increased levels of circulating P-selectin
7. Increased factor VIII as an index of vascular injury in cyclosporine nephrotoxicity
8. Expression of von Willebrand factor, P-selectin (CD62P) and thrombomodulin in human endothelial cells in culture modulated by cyclosporin A
9. Effect of cyclosporine A on the release of tissue factor pathway inhibitor from endothelial cells in heart transplant patients and cell culture
10. Adhesion molecule P-selectin and vascular cell adhesion molecule-1 in enhanced heart allograft arteriosclerosis in the rat
11. Increased soluble P-selectin in peripheral artery disease: a new marker for the progression of atherosclerosis
12. The combined role of P- and E-selectins in atherosclerosis
13. Increased levels of soluble P-selectin in hypercholesterolemic patients
14. Soluble P-selectin in hyperlipidaemia with and without symptomatic vascular disease: relationship with von Willebrand factor
15. Circulating cell adhesion molecules and endothelial markers before and after transluminal angioplasty in peripheral arterial occlusive disease
16. Annotation; a reliable marker of endothelial, cell dysfunction: does it exist?
17. Thromboembolic complications after renal transplantation: a retrospective analysis
18. Vascular complications in 400 consecutive renal allotransplants
19. Thromboembolic complications in cyclosporin-treated kidney allograft recipients
20. Allograft renal vein thrombosis
21. Thromboembolic complications and haemostatic changes in cyclosporin-treated cadaveric kidney allograft recipients
22. Long-term results of renal transplantation in Europe
23. Cyclosporine A enhances platelet aggregation
24. Comparative investigation of the effects of the immunosuppressants cyclosporine A, cyclosporine G, and FK-506 on platelet activation
25. Cyclosporine A enhances agonist-induced aggregation of human platelets by stimulating protein phosphorylation
26. Oxygen free radicals and platelet and granulocyte aggregability in renal transplant patients
27. Nitric oxide functions as an inhibitor of platelet adhesion under flow conditions
28. Thrombosis and hemostasis in renal disease
29. Conversion to mycophenolate mofetil in conjunction with stepwise withdrawal of cyclosporine in stable renal transplant recipients
30. Lithium clearance during the paradoxical natriuresis of hypotonic expansion in man
31. Human factor VIII: purification from commercial factor VIII concentrate, characterization, identification and radiolabeling
32. Comparison of secretion and subcellular localisation of von Willebrand protein with that of thrombospondin and fibronectin in cultured human vascular endothelial cells
33. von Willebrand factor and fibronectin but not thrombospondin are involved in platelet adhesion to the extracellular matrix of human vascular endothelial cells
34. A perfusion chamber developed to investigate platelet interaction in flowing blood with human vessel wall cells, their extracellular matrix, and purified components
35. Cyclosporin inhibits nitric oxide production in medullary ascending limb cultured cells
36. Effect of mycophenolate mofetil (RS-61443) on cytokineproduction: inhibition of superantigen induced cytokines
37. Inhibition of endothelial receptor expression and of T-cell ligand activity by mycophenolate mofetil
38. Serum levels of soluble adhesion molecules in chronic renal failure and dialysis patients